Abiopharma

🔍 Ruemmler Kathryn H. (Executive)

Company: GOLDMAN SACHS GROUP INC (GS)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 135 shares of Common Stock, par value $0.01 per share at $928.85 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,497.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 468 shares of Common Stock, par value $0.01 per share at $929.71 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,029.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 80 shares of Common Stock, par value $0.01 per share at $930.35 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 29,949.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Reflects a weighted average sale price of $928.85 per share, at prices ranging from $928.12 to $929.10 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F2: Reflects a weighted average sale price of $929.71 per share, at prices ranging from $929.15 to $930.12 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F3: Reflects a weighted average sale price of $930.35 per share, at prices ranging from $930.16 to $930.54 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.